Poly (ADP) ribose polymerase inhibition: A potential treatment of malignant peripheral nerve sheath tumor

References

• Farid M, Demicco EG, Garcia R, Ahn L, Merola PR, Cioffi A, Maki RG. Malignant peripheral nerve sheath tumors. Oncologist 2014; 19:193-201; PMID:24470531; http://dx.doi.org/10.1634/theoncologist.2013-0328
   PubMed Web of Science ®Google Scholar
• Gupta G, Maniker A. Malignant peripheral nerve sheath tumors. Neurosurg Focus 2007; 22:E12; PMID:17613203; http://dx.doi.org/10.3171/foc.2007.22.6.13
   PubMedGoogle Scholar
• Friedman JM. Epidemiology of neurofibromatosis type 1. Am J Med Genet 1999; 89:1-6; PMID:10469430; http://dx.doi.org/10.1002/(SICI)1096-8628(19990326)89:1%3c1::AID-AJMG3%3e3.0.CO;2-8
   PubMed Web of Science ®Google Scholar
• Ducatman BS, Scheithauer BW, Piepgras DG, Reiman HM, Ilstrup DM. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer 1986; 57:2006-21; PMID:3082508; http://dx.doi.org/10.1002/1097-0142(19860515)57:10%3c2006::AID-CNCR2820571022%3e3.0.CO;2-6
   PubMed Web of Science ®Google Scholar
• Blakely ML, Spurbeck WW, Pappo AS, Pratt CB, Rodriguez-Galindo C, Santana VM, Merchant TE, Prichard M, Rao BN. The impact of margin of resection on outcome in pediatric nonrhabdomyosarcoma soft tissue sarcoma. J Pediatr Surg 1999; 34:672-5; PMID:10359161; http://dx.doi.org/10.1016/S0022-3468(99)90353-6
   PubMed Web of Science ®Google Scholar
• Carli M, Ferrari A, Mattke A, Zanetti I, Casanova M, Bisogno G, Cecchetto G, Alaggio R, De Sio L, Koscielniak E, et al. Pediatric malignant peripheral nerve sheath tumor: the Italian and German soft tissue sarcoma cooperative group. J Clin Oncol 2005; 23:8422-30; PMID:16293873; http://dx.doi.org/10.1200/JCO.2005.01.4886
   PubMed Web of Science ®Google Scholar
• Zou C, Smith KD, Liu J, Lahat G, Myers S, Wang WL, Zhang W, McCutcheon IE, Slopis JM, Lazar AJ, et al. Clinical, pathological, and molecular variables predictive of malignant peripheral nerve sheath tumor outcome. Ann Surg 2009; 249:1014-22; PMID:19474676; http://dx.doi.org/10.1097/SLA.0b013e3181a77e9a
   PubMed Web of Science ®Google Scholar
• Wong WW, Hirose T, Scheithauer BW, Schild SE, Gunderson LL. Malignant peripheral nerve sheath tumor: analysis of treatment outcome. Int J Radiat Oncol Biol Phys 1998; 42:351-60; PMID:9788415; http://dx.doi.org/10.1016/S0360-3016(98)00223-5
   PubMed Web of Science ®Google Scholar
• Anghileri M, Miceli R, Fiore M, Mariani L, Ferrari A, Mussi C, Lozza L, Collini P, Olmi P, Casali PG, et al. Malignant peripheral nerve sheath tumors: prognostic factors and survival in a series of patients treated at a single institution. Cancer 2006; 107:1065-74; PMID:16881077; http://dx.doi.org/10.1002/cncr.22098
   PubMed Web of Science ®Google Scholar
• McCabe N, Lord CJ, Tutt AN, Martin NM, Smith GC, Ashworth A. BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of Poly (ADP-Ribose) polymerase: an issue of potency. Cancer Biol Ther 2005; 4:934-6; PMID:16251802; http://dx.doi.org/10.4161/cbt.4.9.2141
   PubMed Web of Science ®Google Scholar
• McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S, Giavara S, O'Connor MJ, Tutt AN, Zdzienicka MZ, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 2006; 66:8109-15; PMID:16912188; http://dx.doi.org/10.1158/0008-5472.CAN-06-0140
   PubMed Web of Science ®Google Scholar
• Ame JC, Spenlehauer C, de Murcia G. The PARP superfamily. Bioessays 2004; 26:882-93; PMID:15273990; http://dx.doi.org/10.1002/bies.20085
   PubMed Web of Science ®Google Scholar
• Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434:917-21; PMID:15829967; http://dx.doi.org/10.1038/nature03445
   PubMed Web of Science ®Google Scholar
• Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005; 434:913-7; PMID:15829966; http://dx.doi.org/10.1038/nature03443
   PubMed Web of Science ®Google Scholar
• Plummer ER. Inhibition of poly(ADP-ribose) polymerase in cancer. Curr Opin Pharmacol 2006; 6:364-8; PMID:16753340; http://dx.doi.org/10.1016/j.coph.2006.02.004
   PubMed Web of Science ®Google Scholar
• Meindl A, Ditsch N, Kast K, Rhiem K, Schmutzler RK. Hereditary breast and ovarian cancer: new genes, new treatments, new concepts. Dtsch Arztebl Int 2011; 108:323-30; PMID:21637635; http://dx.doi.org/10.3238/arztebl.2011.0323
   PubMed Web of Science ®Google Scholar
• Nasuno T, Mimaki S, Okamoto M, Esumi H, Tsuchihara K. Effect of a poly(ADP-ribose) polymerase-1 inhibitor against esophageal squamous cell carcinoma cell lines. Cancer Sci 2014; 105:202-10; PMID:24219164; http://dx.doi.org/10.1111/cas.12322
   PubMed Web of Science ®Google Scholar
• Faraonia I, Compagnone M, Lavorgna S, Angelini DF, Cencioni MT, Piras E, Panetta P, Ottone T, Dolci S, Venditti A, et al. BRCA1, PARP1 and γH2AX in acute myeloid leukemia: role as biomarkers of response to the PARP inhibitor olaparib. Biochimica et Biophysica Acta (BBA) - Mol Basis Dis 2015; 1852:462-72; PMID:25483710; http://dx.doi.org/10.1016/j.bbadis.2014.12.001
   PubMed Web of Science ®Google Scholar
• van Vuurden DG, Hulleman E, Meijer OL, Wedekind LE, Kool M, Witt H, Vandertop PW, Wurdinger T, Noske DP, Kaspers GJ, et al. PARP inhibition sensitizes childhood high grade glioma, medulloblastoma and ependymoma to radiation. Oncotarget 2011; 2:984-96; PMID:22184287; http://dx.doi.org/10.18632/oncotarget.362
   PubMed Web of Science ®Google Scholar
• Byers LA, Wang J, Nilsson MB, Fujimoto J, Saintigny P, Yordy J, Giri U, Peyton M, Fan YH, Diao L, et al. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov 2012; 2:798-811; PMID:22961666; http://dx.doi.org/10.1158/2159-8290.CD-12-0112
   PubMed Web of Science ®Google Scholar
• Fang Y, Elahi A, Denley RC, Rao PH, Brennan MF, Jhanwar SC. Molecular characterization of permanent cell lines from primary, metastatic and recurrent malignant peripheral nerve sheath tumors (MPNST) with underlying neurofibromatosis-1. Anticancer Res 2009; 29:1255-62; PMID:19414372
   PubMed Web of Science ®Google Scholar
• Upadhyaya M. Genetic basis of tumorigenesis in NF1 malignant peripheral nerve sheath tumors. Front Biosci (Landmark Ed) 2011; 16:937-51; PMID:21196210; http://dx.doi.org/10.2741/3727
   PubMed Web of Science ®Google Scholar
• Peacock JD, Cherba D, Kampfschulte K, Smith MK, Monks NR, Webb CP, Steensma M. Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors. J Transl Med 2013; 11:213; PMID:24040940; http://dx.doi.org/10.1186/1479-5876-11-213
   PubMed Web of Science ®Google Scholar
• Lazar AJ, Das P, Tuvin D, Korchin B, Zhu Q, Jin Z, Warneke CL, Zhang PS, Hernandez V, Lopez-Terrada D, et al. Angiogenesis-promoting gene patterns in alveolar soft part sarcoma. Clin Cancer Res 2007; 13:7314-21; PMID:18094412; http://dx.doi.org/10.1158/1078-0432.CCR-07-0174
   PubMed Web of Science ®Google Scholar
• Torres KE, Zhu QS, Bill K, Lopez G, Ghadimi MP, Xie X, Young ED, Liu J, Nguyen T, Bolshakov S, et al. Activated MET is a molecular prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumors. Clin Cancer Res 2011; 17:3943-55; PMID:21540237; http://dx.doi.org/10.1158/1078-0432.CCR-11-0193
   PubMed Web of Science ®Google Scholar
• Jin Z, Lahat G, Korchin B, Nguyen T, Zhu QS, Wang X, Lazar AJ, Trent J, Pollock RE, Lev D. Midkine enhances soft-tissue sarcoma growth: a possible novel therapeutic target. Clin Cancer Res 2008; 14:5033-42; PMID:18698021; http://dx.doi.org/10.1158/1078-0432.CCR-08-0092
   PubMed Web of Science ®Google Scholar
• Lopez G, Liu J, Ren W, Wei W, Wang S, Lahat G, Zhu QS, Bornmann WG, McConkey DJ, Pollock RE, et al. Combining PCI-24781, a novel histone deacetylase inhibitor, with chemotherapy for the treatment of soft tissue sarcoma. Clin Cancer Res 2009; 15:3472-83; PMID:19417021; http://dx.doi.org/10.1158/1078-0432.CCR-08-2714
   PubMed Web of Science ®Google Scholar
• Lopez G, Torres K, Liu J, Hernandez B, Young E, Belousov R, Bolshakov S, Lazar AJ, Slopis JM, McCutcheon IE, et al. Autophagic survival in resistance to histone deacetylase inhibitors: novel strategies to treat malignant peripheral nerve sheath tumors. Cancer Res 2011; 71:185-96; PMID:21084276; http://dx.doi.org/10.1158/0008-5472.CAN-10-2799
   PubMed Web of Science ®Google Scholar
• Ren W, Korchin B, Lahat G, Wei C, Bolshakov S, Nguyen T, Merritt W, Dicker A, Lazar A, Sood A, et al. Combined vascular endothelial growth factor receptor/epidermal growth factor receptor blockade with chemotherapy for treatment of local, uterine, and metastatic soft tissue sarcoma. Clin Cancer Res 2008; 14:5466-75; PMID:18765538; http://dx.doi.org/10.1158/1078-0432.CCR-08-0562
   PubMed Web of Science ®Google Scholar
• Goertz O, Langer S, Uthoff D, Ring A, Stricker I, Tannapfel A, Steinau HU. Diagnosis, treatment and survival of 65 patients with malignant peripheral nerve sheath tumors. Anticancer Res 2014; 34:777-83; PMID:24511012
   PubMed Web of Science ®Google Scholar
• Jhanwar SC, Chen Q, Li FP, Brennan MF, Woodruff JM. Cytogenetic analysis of soft tissue sarcomas. Recurrent chromosome abnormalities in malignant peripheral nerve sheath tumors (MPNST). Cancer Genet Cytogenet 1994; 78:138-44; PMID:7828144; http://dx.doi.org/10.1016/0165-4608(94)90081-7
   PubMed Web of Science ®Google Scholar
• Mertens F, Dal Cin P, De Wever I, Fletcher CD, Mandahl N, Mitelman F, Rosai J, Rydholm A, Sciot R, Tallini G, et al. Cytogenetic characterization of peripheral nerve sheath tumours: a report of the CHAMP study group. J Pathol 2000; 190:31-8; PMID:10640989; http://dx.doi.org/10.1002/(SICI)1096-9896(200001)190:1%3c31::AID-PATH505%3e3.0.CO;2-
   PubMed Web of Science ®Google Scholar
• Rahrmann EP, Watson AL, Keng VW, Choi K, Moriarity BS, Beckmann DA, Wolf NK, Sarver A, Collins MH, Moertel CL, et al. Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis. Nat Genet 2013; 45:756-66; PMID:23685747; http://dx.doi.org/10.1038/ng.2641
   PubMed Web of Science ®Google Scholar
• Bradford D, Kim A. Current treatment options for malignant peripheral nerve sheath tumors. Curr Treat Options Oncol 2015; 16:328; PMID:25777573; http://dx.doi.org/10.1007/s11864-015-0328-6
   PubMed Web of Science ®Google Scholar
• Maki RG, D'Adamo DR, Keohan ML, Saulle M, Schuetze SM, Undevia SD, Livingston MB, Cooney MM, Hensley ML, Mita MM, et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol 2009; 27:3133-40; PMID:19451436; http://dx.doi.org/10.1200/JCO.2008.20.4495
   PubMed Web of Science ®Google Scholar
• Kim A, Dombi E, Tepas K, Fox E, Martin S, Wolters P, Balis FM, Jayaprakash N, Turkbey B, Muradyan N, et al. Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas. Pediatr Blood Cancer 2013; 60:396-401; PMID:22961690; http://dx.doi.org/10.1002/pbc.24281
   PubMed Web of Science ®Google Scholar
• Robertson KA, Nalepa G, Yang FC, Bowers DC, Ho CY, Hutchins GD, Croop JM, Vik TA, Denne SC, Parada LF, et al. Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial. Lancet Oncol 2012; 13:1218-24; PMID:23099009; http://dx.doi.org/10.1016/S1470-2045(12)70414-X
   PubMed Web of Science ®Google Scholar
• Rottenberg S, Jaspers JE, Kersbergen A, van der Burg E, Nygren AO, Zander SA, Derksen PW, de Bruin M, Zevenhoven J, Lau A, et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci U S A 2008; 105:17079-84; PMID:18971340; http://dx.doi.org/10.1073/pnas.0806092105
   PubMed Web of Science ®Google Scholar
• Dungey FA, Loser DA, Chalmers AJ. Replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-Ribose) polymerase: mechanisms and therapeutic potential. Int J Radiat Oncol Biol Phys 2008; 72:1188-97; PMID:18954712; http://dx.doi.org/10.1016/j.ijrobp.2008.07.031
   PubMed Web of Science ®Google Scholar
• Weston VJ, Oldreive CE, Skowronska A, Oscier DG, Pratt G, Dyer MJ, Smith G, Powell JE, Rudzki Z, Kearns P, et al. The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo. Blood 2010; 116:4578-87; PMID:20739657; http://dx.doi.org/10.1182/blood-2010-01-265769
   PubMed Web of Science ®Google Scholar
• Menear KA, Adcock C, Boulter R, Cockcroft XL, Copsey L, Cranston A, Dillon KJ, Drzewiecki J, Garman S, Gomez S, et al. 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin- 1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. J Med Chem 2008; 51:6581-91; PMID:18800822; http://dx.doi.org/10.1021/jm8001263
   PubMed Web of Science ®Google Scholar
• Williamson CT, Muzik H, Turhan AG, Zamo A, O'Connor MJ, Bebb DG, Lees-Miller SP. ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors. Mol Cancer Ther 2010; 9:347-57; PMID:20124459; http://dx.doi.org/10.1158/1535-7163.MCT-09-0872
   PubMed Web of Science ®Google Scholar
• Goswami J, Goyal S, Wu H, Moran MS, Haffty BG. Poly(ADP-ribose) polymerase-1 (PARP-1) expression in patients treated with breast-conserving surgery and radiation therapy (BCS plus RT). J Clin Oncol 2010; 28: 15s: 582
   PubMed Web of Science ®Google Scholar
• Gennari ASM, Varesco L, et al. Prognostic significance of BRCA1, PARP1 and PARP2 in sporadic breast cancer. J Clin Oncol 2009; 27s:e22114
   Google Scholar